Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBF 1120 in Japanese patients with advanced solid tumours
NCT02182128Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2006
- Primary completion
- Jun 2009
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 1, open-label, single-arm trial of nintedanib in solid tumor, sponsored by Boehringer Ingelheim. Primary endpoints: Incidence of Dose Limiting Toxicities up to 36 months and Incidence and intensity of Adverse Events up to 36 months. Started Jun 2006; status: completed.
02
Drugs
nintedanib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02182128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182128.